Genes found to play a role in breast cancer's spread to the brain

May 06, 2009

New research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs. The study was published online today in Nature.

According to the study, COX2 and HB-EGF — that induce cancer cell mobility and invasiveness — were found to be genetic mediators in the spread of to the . A third gene, ST6GALNAC5, was shown to provide cancer cells with the capability of exiting the and passing through the blood-brain barrier to enter the brain tissue.

"Our research sheds light on the role these genes play in determining how breast tumor cells break free and, once mobile, how they decide where to attack," said Joan Massagué, PhD, Chair of the Cancer Biology and Genetics Program at MSKCC and a Howard Hughes Medical Institute investigator.

Breast cancer metastasis to the brain typically occurs years after removal of a breast tumor, suggesting that disseminated cancer cells initially lack the specialized functions needed to overtake the dense network of capillaries that constitute the blood-brain barrier. This barrier prevents the entry of circulating cells and regulates the transport of molecules into the brain tissue. To generate brain metastasis, circulating cancer cells must, therefore, be able to pass through the blood-brain barrier and interact with the brain microenvironment.

In the study, Dr. Massagué and his colleagues isolated cancer cells that preferentially targeted the brain from patients with advanced disease. By combining this approach with gene expression profiling, additional testing in mouse model systems, and analysis of a body of clinical data, the investigators identified certain genes and functions that selectively mediate cancer cell passage through the blood-brain barrier.

The authors observed that ST6GALNAC5, an enzyme that is normally active only in , causes a chemical reaction that creates a coating on the surface of breast cancer cells that enhances their ability to breach the blood-brain barrier. Their findings show that breast cancer cells use this brain-specific cell-coating enzyme as a means of infiltrating the brain.

"Our results draw attention to the role of the cell surface coating as a previously unrecognized participant in brain metastasis, and to the possibility of using drugs to disrupt its interactions," said Dr. Massagué. "Further study is necessary to explore the role of these genes in brain metastasis and their interest as therapeutic targets."

The study authors also noted that COX2 and HB-EGF, which prime breast for entrance into the brain, had previously been found to be involved in breast cancer's spread to the lung. This suggests a partial sharing of genetic mediators of metastasis to both the brain and lung and may explain the association of brain and lung relapse in women with breast cancer.

Source: Memorial Sloan-Kettering Cancer Center

Explore further: Low risk of malignancy for small complex adnexal masses

add to favorites email to friend print save as pdf

Related Stories

Genes set scene for metastasis

Apr 11, 2007

Biologists at Memorial Sloan-Kettering Cancer Center (MSKCC) have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor. ...

A genetic 'gang of 4' drives spread of breast cancer

Apr 11, 2007

Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs. The new studies by Howard Hughes Medical Institute researchers reveal that ...

Researchers find clue to stopping breast-cancer metastasis

Nov 17, 2008

If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine ...

Drug combination shrinks breast cancer metastases in brain

Dec 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Recommended for you

Low risk of malignancy for small complex adnexal masses

4 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.